15 Years in Prison for Marketing Fraud

Send us Fan Mail

Is your marketing team building a brand or a federal case? 
In this episode, we deconstruct the $1.2 billion collapse of Boom Care. What looked like a runaway success story in the wound care space was actually a systematic violation of the False Claims Act. We break down the three fatal mistakes that led to 15-year prison sentences for executives: prioritizing reimbursement over medical necessity, incentivizing volume over value, and treating compliance as an afterthought. If you are an executive in biopharma or med-tech, this is a mandatory masterclass in where "aggressive growth" ends and criminal exposure begins. 

Support the show

www.kulkarnilawfirm.com

Episode Transcript

SPEAKER_01 (00:00):
So let's talk about how a medical device business
went from explosive growth tofederal prison sentences.
In this case, boom care ownersran what they thought looked
like a booming operation.
Sales were flying, Medicarerevenue was pouring in.
On paper, it looked like asuccess story.
It was actually a$1.2 billionfraud.

(00:24):
Companies pushed high-cost woundgraph products and marketed them
aggressively to providers,regardless of whether patients
needed them.
Sales schemes were incentivizedon volume.
This is always a thing.
Marketing focused onreimbursement, not medicine.
And doctors were nudged to usethese products even when the

(00:46):
wounds did not qualify forcoverage.
That should be sending youralarm bells going.
That's the first mistake.
But marketing strategy startswith how do we build Medicare
instead of who actually needsthis?
They're already in dangerousterritory.
According to the DOJ, theseproducts were routinely used on
patients who did not meetmedical necessity requirements.

(01:09):
This triggered massive falseclaims to federal healthcare
programs.

SPEAKER_00 (01:15):
Enjoying our content, we'd love to hear more.
Please like, comment, share, andfind more.

SPEAKER_01 (01:23):
Here's the second problem.
Executives treated salespractices as a growth lever, not
a compliance risk.
Commission structures awardedoveruse.
Oversight was weak ornon-existent.
Marketing claims created apipeline of claims that should
never have been submitted in thefirst place.

(01:45):
Third mistake.
Insiders filed a false claimsact lawsuit.
The Department of Justicestepped in.
Criminal charges followed.
The result for prison sentencesof up to 15 years for owners and
executives, plus a$309 millioncivil settlement to resolve

(02:07):
False Claims Act liability.
Here is the message forbiopharma owners and marketers.
You do not get a marketing passjust because your product
exists.
If the marketing drivesmedically unnecessary use,
you're not just creating acompliance risk, you're creating
criminal exposure.
Revenue growth built on badmarketing does not date well.

(02:30):
It turns into subpoenas,indictments, and orange
jumpsuits.
If your sales pitch would make amedical director uncomfortable,
it will absolutely interest theDOJ.
That's the real lesson here.
Call, click, or email.